Outlook on the CAR-T Cell Therapies Industry - In-depth Review of the Various Patents and Affiliated IP Documents
April 25, 2022 05:58 ET
|
Research and Markets
Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
February 14, 2022 05:43 ET
|
Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis
April 06, 2021 08:45 ET
|
Roots Analysis
London, April 06, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CAR-T Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic...
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
November 23, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
October 21, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
June 08, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Chimeric Antigen Receptor (CAR) T-cell Therapy Market to See 44.1% Annual Growth
August 14, 2018 07:00 ET
|
BCC Research
WELLESLEY, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market,...
Chimeric Antigen Receptor Market to See Explosive 44.1% Annual Growth Through 2023
August 08, 2018 06:00 ET
|
BCC Research
WELLESLEY, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market,...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
May 22, 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...
Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference
April 25, 2016 08:30 ET
|
Triumvira Immunologics Inc.
HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...